Medicare and GLP-1 Weight Loss Drugs: Where Things Stand in 2026
Medicare coverage for GLP-1 weight loss medications has been one of the most debated healthcare topics over the past two years. Tens of millions of Medicare beneficiaries could benefit from medications like Wegovy and Zepbound, but a decades-old statutory exclusion has kept these drugs largely out of reach. That is starting to change in 2026, though the landscape remains complicated.
Here is what every Medicare beneficiary needs to know.
The Historical Problem: Medicare's Weight Loss Drug Exclusion
Since 2003, Medicare Part D has contained a statutory exclusion that prohibits coverage of drugs "used for anorexia, weight loss, or weight gain." This was written into the Medicare Modernization Act at a time when weight loss medications were considered lifestyle drugs with questionable efficacy.
The GLP-1 revolution has changed the medical consensus on obesity treatment, but the law has been slow to catch up. The exclusion means that traditional Medicare Part D plans cannot cover Wegovy, Zepbound, Saxenda, or any other medication prescribed solely for weight management.
What Medicare Does Cover: The Diabetes Pathway
Medicare Part D does cover GLP-1 medications when they are prescribed for type 2 diabetes:
- Ozempic (semaglutide 0.5 mg, 1.0 mg, 2.0 mg) for type 2 diabetes
- Mounjaro (tirzepatide 2.5 mg through 15 mg) for type 2 diabetes
- Trulicity (dulaglutide) for type 2 diabetes
- Victoza (liraglutide 1.8 mg) for type 2 diabetes
If you have both obesity and type 2 diabetes, your doctor can prescribe these medications for the diabetes indication, and Medicare Part D will cover them. The active ingredients are the same as Wegovy and Zepbound, though the dosing protocols differ slightly.
Under the Part D redesign that took effect in 2025, Medicare beneficiaries now have a $2,000 annual out-of-pocket cap on prescription drug costs. This means even specialty-tier diabetes medications will not cost you more than $2,000 per year total across all your Part D drugs.
The CMS BALANCE Model: A Game-Changer for 2026
In 2025, the Centers for Medicare and Medicaid Services (CMS) launched the BALANCE Model (Beneficiary Affordability and Long-term Antiobesity Needs through Coverage Expansion). This is the most significant development in Medicare GLP-1 coverage to date.
How the BALANCE Model Works
- Voluntary participation: Medicare Part D plan sponsors and Medicare Advantage plans can choose to participate
- Anti-obesity medication coverage: Participating plans can cover FDA-approved anti-obesity medications, including Wegovy and Zepbound, for beneficiaries with a BMI of 30+ or 27+ with a comorbidity
- Cost-sharing protections: CMS provides financial incentives to plans that keep beneficiary cost-sharing reasonable
- Model duration: The BALANCE Model is a multi-year initiative designed to test whether covering anti-obesity medications for Medicare beneficiaries improves health outcomes and reduces total Medicare spending
How to Know If Your Plan Participates
Not all Medicare plans have opted into the BALANCE Model. To find out if yours does:
- Check Medicare Plan Finder at medicare.gov and search for your specific plan
- Call your plan directly and ask whether they participate in the CMS BALANCE Model for anti-obesity medication coverage
- Review your Annual Notice of Changes (ANOC) that your plan sends each fall, which lists any benefit changes for the upcoming year
- Talk to your State Health Insurance Assistance Program (SHIP), which offers free Medicare counseling
The Treat and Reduce Obesity Act
The Treat and Reduce Obesity Act is federal legislation that would permanently remove the Medicare Part D exclusion for weight loss medications. Key points:
- Bipartisan support: The bill has had co-sponsors from both parties in the House and Senate
- CBO scoring concerns: The Congressional Budget Office has estimated that covering GLP-1s for all Medicare beneficiaries could cost $35 to $50 billion over 10 years, which has slowed its passage
- Current status: As of early 2026, the legislation continues to advance through committee. Advocates are cautiously optimistic about passage, but no timeline is certain
- What it would mean: If passed, all Medicare Part D plans would be required to cover FDA-approved anti-obesity medications, not just plans that voluntarily participate in the BALANCE Model
Medicare Advantage Plans: More Flexibility
Medicare Advantage (MA) plans, offered by private insurers like UnitedHealthcare, Humana, and Aetna, have more flexibility than traditional Medicare to offer supplemental benefits. Some MA plans have begun covering anti-obesity medications as a supplemental benefit or through the BALANCE Model.
If you are choosing a Medicare Advantage plan during open enrollment, specifically ask about GLP-1 coverage for weight management. This is becoming a competitive differentiator among MA plans.
Practical Options for Medicare Beneficiaries in 2026
Here is a summary of your current options:
| Situation | Best Approach |
|---|---|
| You have type 2 diabetes + obesity | Ask your doctor about Ozempic or Mounjaro (covered by Part D for diabetes) |
| Your plan participates in the BALANCE Model | Apply for coverage of Wegovy or Zepbound through your plan |
| You have a Medicare Advantage plan | Check if anti-obesity meds are a supplemental benefit |
| No coverage available | Consider manufacturer patient assistance programs or cash pay options ($300 to $600/month through some clinics) |
| You have supplemental commercial insurance | Check whether your secondary coverage includes anti-obesity medications |
Manufacturer Assistance for Medicare Beneficiaries
Novo Nordisk and Eli Lilly both offer patient assistance programs for Medicare beneficiaries who cannot afford GLP-1 medications:
- Novo Nordisk Patient Assistance Program (PAP): Provides free Wegovy to eligible patients who meet income requirements (typically under 400% of the federal poverty level)
- Eli Lilly Solutions Center: Offers assistance for eligible patients who need Zepbound
- Note: Manufacturer savings cards (coupons) generally cannot be used by Medicare beneficiaries due to federal anti-kickback regulations
What to Watch for in 2026 and Beyond
The Medicare GLP-1 coverage landscape is evolving rapidly. Here is what to monitor:
- BALANCE Model expansion: More plans may join the model in 2026 and 2027
- Treat and Reduce Obesity Act: Congressional action could permanently change the coverage landscape
- New GLP-1 formulations: Oral semaglutide (Rybelsus) for weight loss and next-generation molecules may alter the cost equation
- Open enrollment each fall: Review plan changes annually to ensure you are in the best plan for your needs
Search our directory to find GLP-1 clinics that work with Medicare patients and can help you navigate these evolving coverage options.